Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
T-DXd was associated with a high response rate and durable responses with no new safety signals in previously treated patients with HER2-mutated NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 275 KB
Released: May 30, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Text module presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: October 12, 2022

Slideset presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Released: October 13, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue